7月21日，梯瓦制药工业有限公司与上药控股有限公司签署战略合作协议，上药控股将为梯瓦在中国上市的创新药“氘丁苯那嗪片（安泰坦®Austedo®）”提供保税进口、政府事务、市场准入、全国分销等一站式服务，更好地为人民健康事业服务。On July 21st , Mr. Larry Merizalde, the general manager of Greater China of Teva Pharmaceutical Industries Co., Ltd. has signed a strategic collaboration agreement with Mr. Yongzhong Li, the executive director and vice president of Shanghai Pharmaceuticals Holding Co., Ltd., and the general manager of Shanghai Pharmaceutical Co., Ltd.,. Shaphar will provide Teva with bonded import, government affairs, market access, national distribution and other one-stop services for the innovative drug “Deutetrabenazine Tablet (Austedo®) which was firstly listed in China in order to offer the better services to people’s health.
.png)
由于全球疫情的影响，本次签约采用线上线下结合的创新方式，不仅在线上汇集了来自中国香港、泰国以及以色列的Teva伙伴们，梯瓦大中华区总经理Larry Merizalde与在现场参会的上海医药执行董事、副总裁，上药控股总经理李永忠更是通过科技创新手段同时在战略签约板上签名，让分布在全球的伙伴们共同见证！
It is worth to be mentioned that because of the impact of the global epidemic, the signing ceremony adopted the new-tech way with online and offline combination, and set the online connection with partners from Hong Kong, Thailand, and Israel. Moreover, Larry Merizalde, was attending the meeting in Hongkong, and Mr. Yongzhong Li, was present at the meeting in Shanghai, signed their names on the strategic signing board through innovative technological way in order to be witnessed by partners around the world.It is worth to be mentioned that because of the impact of the global epidemic, the signing ceremony adopted the new-tech way with online and offline combination, and set the online connection with partners from Hong Kong, Thailand, and Israel. Moreover, Larry Merizalde, was attending the meeting in Hongkong, and Mr. Yongzhong Li, was present at the meeting in Shanghai, signed their names on the strategic signing board through innovative technological way in order to be witnessed by partners around the world.
.png)
.png)
.png)
.png)
上药控股助理总经理、上药国际供应链总经理宋潞潞表示，非常荣幸可以现场见证梯瓦与上药控股的战略合作，也对梯瓦的支持与信任表示衷心的感谢。上药控股从一个区域性公司发展成为目前中国最大的医药商业公司之一，秉承“服务为荣”的经营理念，得到了众多像梯瓦一样全球领先的制药企业的认可。同时，在未来，全新的进口平台—上药国际供应链有限公司也将依靠临港自由贸易区的优惠政策，整合全球资源配置，争取为梯瓦提供更便利、更优质的服务。
Mrs. Lulu Song, the associated general manager of Shaphar, the general manager of SPLG, claimed that it was a great honor to witness the strategic cooperation between Teva and Shaphar and expressed thanks to Teva for the support and trust. Shaphar has grown from a regional company, into one of the largest pharmaceutical commercial companies in China. By adhering to the business philosophy of "to be service-oriented", Shaphar has received recognition by many leading pharmaceutical companies in the world like Teva. In addition, in the future, the new import platform -- Shanghai Pharmaceutical Lin-gang Special Area Co., Ltd. will also rely on the preferential policies of Lin-gang Free Trade Zone, integrating global resources allocation, and keeping on providing Teva with more convenient and satisfactory services.
.png)
作为治疗与亨廷顿病有关的舞蹈病和成人迟发性运动障碍的有效药物，依托对罕见病有益的国家政策，安泰坦®Austedo®将会为更多的中国患者带来福音。同时，上海医药作为中国最大的药品进口分销平台，相信在未来一定可以与梯瓦共同努力，推动中国医疗事业的蓬勃发展。
As the effective treatment for chorea associated with Huntington's disease (HD) and Tardive Dyskinesia (TD) in adults, Austedo® will benefit more patients in China based on the beneficial national policy for rare diseases. At the same time, as the largest pharmaceutical import and distribution platform in China, Shaphar will make joint efforts with Teva to promote the vigorous development of China's medical industry.
.png)
亨廷顿病（HD）是一种罕见的致命的神经退化性疾病，亚洲每十万人中大约有0.4人患病，平均发病年龄为40岁。舞蹈病（无意识的、随机和突然的扭动和/或转动）是这种疾病最为显著的表现之一，发生在大约90%的病人当中。
About chorea associated with Huntington's disease (HD)
Huntington's disease is a rare but fatal neurodegenerative disease, affecting about 0.4 per 100,000 people in Asia, with an average age of 40 years. Chorea (involuntary, random and sudden twists and/or turns) is one of the most prominent signs of the disease and occurs in approximately 90% of patients.
迟发性运动障碍（TD）是一种使人衰弱的运动紊乱，以舌头、嘴唇、脸、躯体和四肢部位的重复且不可控的运动为特征。TD在长期接受抗精神病药治疗的中国的精神分裂症患者当中的患病率为33.7%，可能是由某些用于治疗精神健康状况的药物引起的，这意味着使用这些药物的精神分裂症患者中有三分之一可能患有TD。
About Tardive Dyskinesia (TD) in adults
Tardive Dyskinesia is a debilitating movement disorder characterized by repetitive and uncontrollable movements of the tongue, lips, face, body, and limbs. TD has a prevalence of 33.7% among Chinese schizophrenia patients receiving long-term antipsychotic treatment and may be caused by certain drugs used to treat mental health conditions, meaning that one-third of schizophrenics using these drugs may have TD.
梯瓦是一家全球性的医药公司，也是全球最大的仿制药公司，成立于1901年。同时，致力于成为全球仿制药和生物制药的领导者，开发及生产优质仿制药、创新的专科药物及药物活性成分，以提高和改善病患的生活质量。
About Teva
Founded in 1901, Teva is a global pharmaceutical company, as well as the largest generic drug company in the world. Meanwhile, Teva is committed to being a global leader in generic drugs and biopharmaceuticals, developing and producing quality generic drugs, innovative specialty drugs and active ingredients to improve living quality of patients.
安泰坦®是梯瓦创新研发的原研药，于2017年4月获得美国FDA批准，是FDA首次批准的氘代产品，也是针对与亨廷顿病有关的舞蹈病的历史上第二个药物；在美国的获批适应症包括与亨廷顿病（HD）有关的舞蹈病以及成人迟发性运动障碍（TD）。其中TD适应症被批准为突破性治疗。FDA对安泰坦®的批准代表了HD患者的一个重要的新治疗选择。
About Austedo®
Austedo®, a drug innovatively developed by Teva, was approved by FDA in April 2017. It is the first FDA approved deuterium product and the second drug in the history related to chorea associated with Huntington's disease (HD). Approved indications in the United States include Chorea associated with Huntington's disease (HD) and Tardive Dyskinesia (TD) in adults. The TD indication was approved as a breakthrough therapy. FDA approval of Austedo® represents an important new treatment option for HD patients.
